Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
about
The role of additional radiotherapy for primary central nervous system lymphomaThe role of additional radiotherapy for primary central nervous system lymphoma (PCNSL)Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphomaThe vanishing role of whole brain radiotherapy for primary central nervous system lymphomaPrimary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcomeAdvances in Primary Central Nervous System Lymphoma.High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.Early response to high-dose methotrexate, vincristine, and procarbazine chemotherapy-adapted strategy for primary CNS lymphoma: no consolidation therapy for patients achieving early complete response.Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma.Biology and treatment of primary central nervous system lymphoma.Treatment options for central nervous system lymphomas in immunocompetent patients.Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade).Progress in central nervous system lymphomas.Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatmentHigh-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.Low-dose whole brain radiotherapy with tumor bed boost after methotrexate-based chemotherapy for primary central nervous system lymphoma.High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphomaEarly complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma.Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?Use of a deformable atlas to identify cryptic critical structures in the treatment of glioblastoma multiformePituitary lymphoma developing within pituitary adenoma.Rituximab monotherapy for patients with recurrent primary CNS lymphoma.Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma.Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoCognitive functions in primary CNS lymphoma after single or combined modality regimens.A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics.Isolated central nervous system relapse in a patient with diffuse large B cell lymphoma.Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.Advantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institution.Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center.Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disordersRituximab associated neutropenia: description of three cases and an insight into the underlying pathogenesisRadiation dose-volume effects in the brain.Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experienceRituximab is associated with improved survival for aggressive B cell CNS lymphoma.
P2860
Q24193995-4AA026D2-7793-4CE1-B022-86C4DD88F9CBQ24236186-2F42F944-BD52-4BFD-A144-4D18979E86FDQ27013785-94DD6494-0F13-40D2-AECD-85DEF4E5AC6DQ27025006-6453EB0E-C330-4AA8-90F2-73CEB6928692Q30411688-D3F05E7C-0A25-48E9-9458-5F3604235207Q30457046-E10DC797-2CEB-4D5B-8842-1E0A8B423766Q31007237-F15FBAE1-6835-46BF-A036-670A787D1D03Q33381778-2FEF8DC3-C139-4C17-933D-B3DAF402CF74Q33409443-E10BBA08-01DD-4F93-8452-102121DCCBA6Q33426914-84B356A1-6C2B-4A93-A805-69D084E377CCQ33475480-64E4035D-CFBC-4703-9219-A0DB2CEDA7E9Q33510785-1699FF28-A791-46AF-85FF-F2CE3FAB761CQ33583302-F30E912A-CE98-4012-BE1C-A0E9AFD392C6Q33934406-AE64FD89-5FDD-4BC4-BE0F-9A7677F94EDFQ33946604-B8472BDD-6C0D-437F-9E24-ECAA22553112Q33981252-CD6280FA-57A6-4F1A-A03E-FE79B77FBA12Q34036804-9ADD1721-8704-4647-AF31-DD6976A45952Q34043390-ADCB1961-705F-4DB1-8EB1-5EDD7F275330Q34132988-D97F53E8-313A-48BF-859F-C4234DAB58B8Q34132992-6C102D2B-582A-480B-ABF1-29CE85476E28Q34190457-E79C29A6-77AF-4A61-97C8-177EBEAC0897Q34213759-54902A23-DE58-4416-BCD4-F37385812E83Q34243080-9BBC70F2-1292-4040-8F87-42C5BECA752EQ34686155-FE8B5931-93D0-4FAB-9562-94C2DECAC5D6Q34753447-8FA47EDC-DE11-4C04-B40C-C598410BB7A7Q34943963-954001B6-76CD-44AE-8303-ACFF43AAC2C1Q35633840-4EECCF9F-BEC8-4B37-9C3F-3B6C8CDB95DFQ35639567-973E1F1C-ABEB-46A2-BA39-2724F7B99662Q35757506-E5B1CD9A-26BF-4E0F-BAEE-5AAF6CA58DCAQ35783021-DE36E834-EF17-4575-A327-FF995805D9C1Q35867843-E4BF464A-D056-46A3-8E70-5AAC36561B23Q35869493-6FF2CCCA-91B7-4BF2-9680-C9483E7F7D13Q35914118-FCED3901-06F3-44CE-8418-D840C2E41CFAQ36261369-B51B7537-4F10-4DC7-9032-CCC1C65948E0Q36374813-E2EF595C-9953-473A-897F-0A54864F23E6Q36516345-646923AE-22BD-4F19-A9AD-37587198F060Q36560171-7EF3CDFE-0165-4D5F-9A80-873D385F03DDQ36712741-AE337399-01AC-470F-83E1-A575F0D8B4DDQ36825376-14B6244D-E052-4B44-BF7E-217243DB4FAEQ37021529-7634ED95-E9B7-4BEB-9C1B-87EC9EED76BC
P2860
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Combined immunochemotherapy wi ...... iagnosed primary CNS lymphoma.
@ast
Combined immunochemotherapy wi ...... iagnosed primary CNS lymphoma.
@en
type
label
Combined immunochemotherapy wi ...... iagnosed primary CNS lymphoma.
@ast
Combined immunochemotherapy wi ...... iagnosed primary CNS lymphoma.
@en
prefLabel
Combined immunochemotherapy wi ...... iagnosed primary CNS lymphoma.
@ast
Combined immunochemotherapy wi ...... iagnosed primary CNS lymphoma.
@en
P2093
P356
P1476
Combined immunochemotherapy wi ...... iagnosed primary CNS lymphoma.
@en
P2093
Barbara Grant
David Schiff
Denise D Correa
Gaurav D Shah
Jeffrey J Raizer
Joachim Yahalom
Lauren E Abrey
Renato LaRocca
Rose K Lai
P304
P356
10.1200/JCO.2007.12.5062
P407
P577
2007-10-01T00:00:00Z